A DNA methylation marker test performed on urine samples obtained from patients with non-muscle-invasive bladder cancer (NMIBC) has the ability to predict tumor recurrence with both high sensitivity and specificity. The urine test, which measures three distinct DNA methylation markers, detected …

READ FULL ARTICLE Curated publisher From Forbes